VMB-100 / Versameb - LARVOL DELTA

A Phase 2a Study To Evaluate VMB-100 In Females With Stress Urinary Incontinence (clinicaltrials.gov) - P2 | N=0 | Withdrawn | Sponsor: Versameb AG | N=30 ➔ 0 | Not yet recruiting ➔ Withdrawn

Enrollment change • First-in-human • Trial withdrawal • Urinary Incontinence • Urology

A Phase 2a Study To Evaluate VMB-100 In Females With Stress Urinary Incontinence (clinicaltrials.gov) - P2 | N=30 | Not yet recruiting | Sponsor: Versameb AG | Trial completion date: Nov 2028 ➔ Apr 2029 | Trial primary completion date: Jun 2027 ➔ Nov 2027

Trial completion date • Trial primary completion date • Urinary Incontinence • Urology

A Phase 2a Study To Evaluate VMB-100 In Females With Stress Urinary Incontinence (clinicaltrials.gov) - P2 | N=30 | Not yet recruiting | Sponsor: Versameb AG | Trial completion date: Nov 2027 ➔ Nov 2028 | Initiation date: Apr 2024 ➔ Apr 2025 | Trial primary completion date: Jun 2026 ➔ Jun 2027

Trial completion date • Trial initiation date • Trial primary completion date • Urinary Incontinence • Urology

A Phase 2a Study To Evaluate VMB-100 In Females With Stress Urinary Incontinence (clinicaltrials.gov) - P2 | N=30 | Not yet recruiting | Sponsor: Versameb AG

New P2 trial • Urinary Incontinence • Urology